FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324137024> ?p ?o ?g. }

• W4324137024 endingPage "493" @default.
• W4324137024 startingPage "493" @default.
• W4324137024 abstract "493 Background: Neoadjuvant cisplatin-based combination chemotherapy (NAC) improves survival in muscle invasive bladder cancer (MIBC). However, response rates and survival remain suboptimal. We sought to evaluate the efficacy of cabazitaxel with cisplatin in this patient group. These patients have now been followed for survival status for 5 years post NAC and radical cystectomy. Methods: This was a single arm (Simon 2 stage), phase 2 study. Patients with MIBC were included if fit to receive NAC and to undergo radical cystectomy. 26 evaluable patients were required to detect an objective response rate (ORR) of >35% with 80% power. ORR was defined as pathological complete response (pCR) plus partial response (pathological downstaging, ≥T2 at diagnosis to ≤T1 at cystectomy). Treatment was with cisplatin 70mg/m 2 and cabazitaxel 15mg/m 2 on day 1 of a 21-day cycle, for 4 cycles prior to surgery. Toxicity was recorded using CTCAE v.4.03. QoL data was assessed during and after chemotherapy using EQ-5D-5L and EORTC-QLQ-C30, BLM30 questionnaires. Patients were followed for 5 years post cystectomy for progression free survival (PFS) and overall survival (OS). Results: ORR was seen in 15 out of 26 evaluable patients, 57.7%, with 24.6% achieving pCR. 1 out of 15 patients who achieved ORR died due to disease progression in the 5 year follow up period. The median PFS and OS were not reached by the 5 year follow up time point with a 5 year survival rate of 65.4% being seen in this patient cohort. Median OS in non-responders (11 patients) was 20.5 months and 5 year survival rate for the non-responders was 36.4% compared to 93.3% for responders. Conclusions: Neoadjuvant cabazitaxel with cisplatin chemotherapy is an effective regimen with 65.4% patients alive and progression-free at 5 years. It also indicates that ORR (and not just pCR), is a good predictor of patient survival at 5 years post radical cystectomy with only 1 out of 15 patients who achieved ORR progressing and dying in this period. However, in current clinical practice, there are no validated predictive biomarkers regarding potential response to NAC. Taken together with our previously published data, cabazitaxel with cisplatin as neoadjuvant chemotherapy is a safe, well-tolerated and effective regimen and should be compared to the regimens e.g. cisplatin/gemcitabine considered as standard in this setting. Clinical trial information: NCT01616875 ." @default.
• W4324137024 created "2023-03-15" @default.
• W4324137024 creator A5005853951 @default.
• W4324137024 creator A5010932236 @default.
• W4324137024 creator A5012325128 @default.
• W4324137024 creator A5024290082 @default.
• W4324137024 creator A5034586479 @default.
• W4324137024 creator A5042232173 @default.
• W4324137024 creator A5045300244 @default.
• W4324137024 creator A5047892230 @default.
• W4324137024 creator A5053173599 @default.
• W4324137024 creator A5060680132 @default.
• W4324137024 creator A5066638654 @default.
• W4324137024 creator A5069535975 @default.
• W4324137024 creator A5070417221 @default.
• W4324137024 creator A5073519021 @default.
• W4324137024 creator A5079519652 @default.
• W4324137024 date "2023-02-20" @default.
• W4324137024 modified "2023-10-16" @default.
• W4324137024 title "The Bristol Bladder Trial: Five year outcomes in patients treated with neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder." @default.
• W4324137024 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.493" @default.
• W4324137024 hasPublicationYear "2023" @default.
• W4324137024 type Work @default.
• W4324137024 citedByCount "0" @default.
• W4324137024 crossrefType "journal-article" @default.
• W4324137024 hasAuthorship W4324137024A5005853951 @default.
• W4324137024 hasAuthorship W4324137024A5010932236 @default.
• W4324137024 hasAuthorship W4324137024A5012325128 @default.
• W4324137024 hasAuthorship W4324137024A5024290082 @default.
• W4324137024 hasAuthorship W4324137024A5034586479 @default.
• W4324137024 hasAuthorship W4324137024A5042232173 @default.
• W4324137024 hasAuthorship W4324137024A5045300244 @default.
• W4324137024 hasAuthorship W4324137024A5047892230 @default.
• W4324137024 hasAuthorship W4324137024A5053173599 @default.
• W4324137024 hasAuthorship W4324137024A5060680132 @default.
• W4324137024 hasAuthorship W4324137024A5066638654 @default.
• W4324137024 hasAuthorship W4324137024A5069535975 @default.
• W4324137024 hasAuthorship W4324137024A5070417221 @default.
• W4324137024 hasAuthorship W4324137024A5073519021 @default.
• W4324137024 hasAuthorship W4324137024A5079519652 @default.
• W4324137024 hasConcept C121608353 @default.
• W4324137024 hasConcept C126322002 @default.
• W4324137024 hasConcept C126894567 @default.
• W4324137024 hasConcept C141071460 @default.
• W4324137024 hasConcept C143998085 @default.
• W4324137024 hasConcept C203092338 @default.
• W4324137024 hasConcept C2775910329 @default.
• W4324137024 hasConcept C2776694085 @default.
• W4324137024 hasConcept C2777899217 @default.
• W4324137024 hasConcept C2778239845 @default.
• W4324137024 hasConcept C2778292576 @default.
• W4324137024 hasConcept C2778822529 @default.
• W4324137024 hasConcept C2778971682 @default.
• W4324137024 hasConcept C2780192828 @default.
• W4324137024 hasConcept C2780352672 @default.
• W4324137024 hasConcept C530470458 @default.
• W4324137024 hasConcept C535046627 @default.
• W4324137024 hasConcept C71924100 @default.
• W4324137024 hasConceptScore W4324137024C121608353 @default.
• W4324137024 hasConceptScore W4324137024C126322002 @default.
• W4324137024 hasConceptScore W4324137024C126894567 @default.
• W4324137024 hasConceptScore W4324137024C141071460 @default.
• W4324137024 hasConceptScore W4324137024C143998085 @default.
• W4324137024 hasConceptScore W4324137024C203092338 @default.
• W4324137024 hasConceptScore W4324137024C2775910329 @default.
• W4324137024 hasConceptScore W4324137024C2776694085 @default.
• W4324137024 hasConceptScore W4324137024C2777899217 @default.
• W4324137024 hasConceptScore W4324137024C2778239845 @default.
• W4324137024 hasConceptScore W4324137024C2778292576 @default.
• W4324137024 hasConceptScore W4324137024C2778822529 @default.
• W4324137024 hasConceptScore W4324137024C2778971682 @default.
• W4324137024 hasConceptScore W4324137024C2780192828 @default.
• W4324137024 hasConceptScore W4324137024C2780352672 @default.
• W4324137024 hasConceptScore W4324137024C530470458 @default.
• W4324137024 hasConceptScore W4324137024C535046627 @default.
• W4324137024 hasConceptScore W4324137024C71924100 @default.
• W4324137024 hasIssue "6_suppl" @default.
• W4324137024 hasLocation W43241370241 @default.
• W4324137024 hasOpenAccess W4324137024 @default.
• W4324137024 hasPrimaryLocation W43241370241 @default.
• W4324137024 hasRelatedWork W2012557700 @default.
• W4324137024 hasRelatedWork W2125696407 @default.
• W4324137024 hasRelatedWork W2401969674 @default.
• W4324137024 hasRelatedWork W2598074874 @default.
• W4324137024 hasRelatedWork W2603025253 @default.
• W4324137024 hasRelatedWork W2980761415 @default.
• W4324137024 hasRelatedWork W3144473405 @default.
• W4324137024 hasRelatedWork W3202515919 @default.
• W4324137024 hasRelatedWork W4315628570 @default.
• W4324137024 hasRelatedWork W4324137024 @default.
• W4324137024 hasVolume "41" @default.
• W4324137024 isParatext "false" @default.
• W4324137024 isRetracted "false" @default.
• W4324137024 workType "article" @default.